Final-Program-ATS-2023-AP.vp

134

MONDAY • MAY 22

9:42 ATS Statement on Race and Ethnicity in Pulmonary Function Test Interpretation N. Bhakta, MD, San Francisco, CA 9:57 ATS Statement on Priorities for Interventions to Address Health Disparities in Lung Nodule Management K. Steiling, MD, MSc, Boston, MA 10:12 Guideline Implementation J. Ruminjo, MD, New York, NY 10:20 Panel discussion CLINICAL SCIENTIFIC SYMPOSIUM B1 3 BREAKING NEWS: CLINICAL TRIAL RESULTS IN PULMONARY MEDICINE 9:00-11:00 am Walter E. Washington Convention Center Ballroom C (Level 3) Target Audience Clinicians, research scientists, and other allied health professionals Objectives At the conclusion of this session, the participant will be able to: • gain new findings about emerging inhaled therapy for pulmonary arterial hypertension • learn new findings about the effects new drugs and new biologics to treat COPD symptoms and exacerbation frequency • learn new findings about novel dual target biologic formulations for treating asthma This session will provide late-breaking information on leading clinical trials affecting the pulmonary community. Chairing: P. Lai, MD, MPH, ATSF, Boston, MA J. Lee, MD, ATSF, Aurora, CO 9:00 Welcome and Introduction 9:04 Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study R.P. Frantz, MD, Rochester, MN 9:24 Questions and Answers 9:32 Effect of Ensifentrine, a Novel PDE3 and PDE4 Inhibitor, on Lung Function, Symptoms and Exacerbations in Patients With COPD: The Enhance Trials A. Anzueto, MD, San Antonio, TX 9:52 Questions and Answers 9:59 Targeting of TSLP and IL-13 by the Novel Nanobody® Molecule SAR443765 Reduces FeNO in Asthma

10:19 Questions and Answers 10:27 Efficacy and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease With Type 2 Inflammation S.Bhatt, MD, Birmingham, AL, USA 10:47 Questions and Answers 10:55 Wrap Up BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL LATE BREAKING MINI SYMPOSIUM COVID SEVERITY, OUTCOMES, AND DISPARITIES: FROM MOLECULE TO COMMUNITY B14 Oral Presentations: 9:00 Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation/ E. Alfaro, Madrid, Spain 9:12 Natural Anti-ACE2 IgM Levels Are Associated With Protection From Severe COVID-19/ E.L. Mitchell, Charlottesville, VA 9:24 Dual Energy CT (DECT)-derived Ventilation/perfusion (V’/Q’) Mismatch Following COVID-19 Infection: Preliminary Results From the Lung Microvascular and Parenchymal Sequelae (Lung-MaPS) of COVID-19 Study/ E. Oelsner, New York, NY 9:36 Longitudinal Evaluation of Quantitative Computed Tomography Measurements and Diffusion Capacity of the Lung in Recovered COVID-19 Patients With Normal Chest Computed Tomography Scans/ S. Lee, Bethesda, MD 9:48 Development and External Validation of a National Veterans COVID-19 Machine Learning Model/ S. Govindan, Kansas City, MO 10:00 Association of Smoking History With COVID-19 Infection, Hospitalization and Death in the C4R Study/ P. Balte, New York, NY 10:12 Living Life in the Fast Lane: Sinus Tachycardia Following COVID-19 and It’s Implications/ B. Amir-Kabirian, Charleston, WV 10:24 Association of Delirium With Functional and Cognitive Outcomes Among Older Survivors of a COVID-19 Hospitalization/ R. Kaushik, New Haven, CT 9:00 a.m. - 11:00 a.m. Walter E. Washington Convention Center Room 202 A (Level 2) Chairing: C.H. Weiss, MD, Evanston, IL K.M. Potter, PhD, RN, CNE, Pittsburgh, PA

Following Single Dose Exposure B.T. Suratt, MD, Cambridge, MA

ATS 2023 • Washington, DC